Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model

Vascular endothelial growth factor (VEGF)-neutralizing therapy with bevacizumab has become increasingly important for treating colorectal cancer. It was demonstrated that second-line chemotherapy together with bevacizumab after disease progression (PD) on first-line therapy including bevacizumab sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwai, Toshiki, Sugimoto, Masamichi, Harada, Suguru, Yorozu, Keigo, Kurasawa, Mitsue, Yamamoto, Kaname
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933557/
https://www.ncbi.nlm.nih.gov/pubmed/27350037
http://dx.doi.org/10.3892/or.2016.4902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933557/
https://www.ncbi.nlm.nih.gov/pubmed/27350037
http://dx.doi.org/10.3892/or.2016.4902

Ejemplares similares